Long-chain ω-3 polyunsaturated fatty acid intake from fish and other dietary sources may provide a potential strategy to improve survival after breast cancer, a new study published online early in the journal Cancer has found.
For the study, researchers analyzed data from 1,463 women newly diagnosed with first primary breast cancer from a population-based follow-up study conducted on Long Island, New York. All participants had been interviewed an average of about 3 months after diagnosis to assess risk and prognostic factors. During a median follow-up of 14.7 years, 485 deaths occurred. Researchers in this study were investigated whether dietary ω-3 polyunsaturated fatty acid intake benefits survival after breast cancer.
Results of the study showed that all-cause mortality was reduced among women with breast cancer who reported the highest quartile of intake for tuna, other baked/broiled fish, and the dietary long-chain ω-3 polyunsaturated fatty acids docosahexanoic acid and eicosapentaenoic acid, compared with women who reported no intake of those fish or fatty acids.
Long-chain ω-3 polyunsaturated fatty acid intake from fish and other dietary sources may provide a potential strategy to improve survival after breast cancer
All-cause mortality was reduced by 16% to 34% among women with breast cancer who reported a high intake of fish and long-chain ω-3 PUFAs. Long-chain ω-3 PUFA intake from fish and other dietary sources may provide a potential strategy to improve survival after breast cancer.
Enjoying our content?
Thanks for visiting Oncology Nurse Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Oncology Nurse Advisor. Register for free and gain unlimited access to:
- Clinical Updates
- Evidence-Based Guidance
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.